MCID: NVS001
MIFTS: 44

Neovascular Glaucoma malady

Categories: Eye diseases, Rare diseases

Aliases & Classifications for Neovascular Glaucoma

Aliases & Descriptions for Neovascular Glaucoma:

Name: Neovascular Glaucoma 12 56 14
Glaucoma, Neovascular 42 69
Secondary Angle-Closure Glaucoma with Rubeosis 12
Glaucoma Neovascular 52

Characteristics:

Orphanet epidemiological data:

56
neovascular glaucoma
Prevalence: 1-5/10000 (Europe);

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Eye diseases
Orphanet: 56  
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:1687
MeSH 42 D015355
Orphanet 56 ORPHA94058
MESH via Orphanet 43 D015355
UMLS via Orphanet 70 C0017609
UMLS 69 C0017609

Summaries for Neovascular Glaucoma

MalaCards based summary : Neovascular Glaucoma, also known as glaucoma, neovascular, is related to retinoschisis and retinitis, and has symptoms including photophobia, retinal detachment and visual loss. An important gene associated with Neovascular Glaucoma is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Pathways in cancer and Endochondral Ossification. The drugs Bevacizumab and Ranibizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and testes.

Related Diseases for Neovascular Glaucoma

Diseases related to Neovascular Glaucoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 81)
id Related Disease Score Top Affiliating Genes
1 retinoschisis 11.3
2 retinitis 10.4
3 endotheliitis 10.3
4 hyperinsulinism 10.2 TGFB2 VEGFA
5 melanoma 10.2
6 isolated plagiocephaly 10.2 PGF VEGFA
7 neuropathy with hearing impairment 10.2 PGF VEGFA
8 retinal vein occlusion 10.2
9 cryptosporidiosis 10.2 PGF VEGFA
10 central retinal vein occlusion 10.2
11 athabaskan brainstem dysgenesis syndrome 10.2 RS1 VEGFA
12 rubeosis iridis 10.1
13 biemond syndrome ii 10.1 RS1 VEGFA
14 multilocular clear cell renal cell carcinoma 10.1 RS1 VEGFA
15 parameningeal embryonal rhabdomyosarcoma 10.1 PGF VEGFA
16 oppositional defiant disorder 10.1 PGF VEGFA
17 brucella canis brucellosis 10.1 RS1 VEGFA
18 choroiditis 10.1
19 leukoplakia of vagina 10.1 IER3IP1 VEGFA
20 vulvitis 10.1 PGF VEGFA
21 mixed gonadal dysgenesis 10.0 OPTN TGFB2
22 exophthalmic ophthalmoplegia 10.0 PGF VEGFA
23 adult infiltrating astrocytic neoplasm 10.0 RS1 TGFB2 VEGFA
24 upper respiratory tract disease 10.0 RS1 TGFB2 VEGFA
25 prostate disease 10.0 OPTN VEGFA
26 anterograde amnesia 10.0 RS1 VEGFA
27 pelvic varices 10.0 OPTN VEGFA
28 cataract 10.0
29 retinal artery occlusion 10.0
30 hypertrophy of breast 10.0 OPTN TGFB2
31 acquired hyperkeratosis 10.0 OPTN SLC6A13
32 epidermolysis bullosa simplex, sutosomal recessive 2 10.0 TGFB2 VEGFA
33 retinal detachment 9.9
34 uveal melanoma 9.9
35 carotid artery occlusion 9.9
36 ischemia 9.9
37 neurofibromatosis 9.9
38 pseudopterygium 9.9 OPTN VEGFA
39 mechanical strabismus 9.9 IER3IP1 OPTN
40 astigmatism 9.9 OPTN RS1
41 venous insufficiency 9.9 OPTN TGFB2 VEGFA
42 coats disease 9.9
43 artery disease 9.9
44 carotid artery disease 9.9
45 central retinal artery occlusion 9.9
46 neurofibromatosis, type 1 9.9
47 conjugate gaze palsy 9.9 OPTN SLC6A13 VEGFA
48 colorectal cancer 5 9.8 OPTN SLC6A13 TGFB2
49 substance-induced psychosis 9.8 IER3IP1 OPTN VEGFA
50 retinal ischemia 9.8

Graphical network of the top 20 diseases related to Neovascular Glaucoma:



Diseases related to Neovascular Glaucoma

Symptoms & Phenotypes for Neovascular Glaucoma

Human phenotypes related to Neovascular Glaucoma:

56 32 (show all 16)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 photophobia 56 32 Frequent (79-30%) HP:0000613
2 retinal detachment 56 32 Very rare (<4-1%) HP:0000541
3 visual loss 56 32 Very frequent (99-80%) HP:0000572
4 retinal vascular proliferation 56 32 Occasional (29-5%) HP:0007850
5 ocular pain 56 32 Frequent (79-30%) HP:0200026
6 abnormality of the optic nerve 56 32 Frequent (79-30%) HP:0000587
7 corneal stromal edema 56 32 Occasional (29-5%) HP:0012040
8 abnormality of the anterior chamber 56 32 Occasional (29-5%) HP:0000593
9 increased intraocular pressure 56 32 Frequent (79-30%) HP:0007906
10 visual acuity test abnormality 56 32 Frequent (79-30%) HP:0030532
11 iris neovascularization 56 32 Very frequent (99-80%) HP:0011497
12 retinal vein occlusion 56 32 Very frequent (99-80%) HP:0012636
13 abnormality of central retinal artery 56 32 Frequent (79-30%) HP:3000032
14 glaucoma 56 Obligate (100%)
15 abnormality of the uvea 56 Frequent (79-30%)
16 abnormality of the posterior segment of the globe 56 Occasional (29-5%)

Drugs & Therapeutics for Neovascular Glaucoma

Drugs for Neovascular Glaucoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 48)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
2
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1 347396-82-1 459903
3 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
4 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
5 Mitomycins Phase 4,Phase 3,Phase 2
6 Endothelial Growth Factors Phase 4,Phase 3,Phase 2,Phase 1
7 Mitogens Phase 4,Phase 3,Phase 2,Phase 1
8
Triamcinolone Approved, Vet_approved Phase 2, Phase 3 124-94-7 31307
9
Dorzolamide Approved Phase 2, Phase 3 120279-96-1 3154 5284549
10
Timolol Approved Phase 2, Phase 3 26839-75-8 33624 5478
11 Alkylating Agents Phase 3,Phase 2
12 Anti-Bacterial Agents Phase 3,Phase 2
13 Antibiotics, Antitubercular Phase 3,Phase 2
14 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
15 Anti-Inflammatory Agents Phase 2, Phase 3
16 glucocorticoids Phase 2, Phase 3
17 Hormone Antagonists Phase 2, Phase 3
18 Hormones Phase 2, Phase 3
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
20 Immunosuppressive Agents Phase 2, Phase 3
21 triamcinolone acetonide Phase 2, Phase 3
22 Triamcinolone diacetate Phase 2, Phase 3
23 Triamcinolone hexacetonide Phase 2, Phase 3
24 Pharmaceutical Solutions Phase 2, Phase 3, Phase 1
25 Adrenergic Agents Phase 2, Phase 3
26 Adrenergic Antagonists Phase 2, Phase 3
27 Adrenergic beta-Antagonists Phase 2, Phase 3
28 Anti-Arrhythmia Agents Phase 2, Phase 3
29 Antihypertensive Agents Phase 2, Phase 3
30 Carbonic Anhydrase Inhibitors Phase 2, Phase 3
31 Lubricant Eye Drops Phase 2, Phase 3
32 Neurotransmitter Agents Phase 2, Phase 3
33 Ophthalmic Solutions Phase 2, Phase 3
34 Tetrahydrozoline Phase 2, Phase 3
35 insulin Phase 2, Phase 3
36 Insulin, Globin Zinc Phase 2, Phase 3
37 Anesthetics Phase 2
38 Antibodies Phase 1
39 Antibodies, Monoclonal Phase 1
40 Immunoglobulins Phase 1
41
Epinephrine Approved, Vet_approved 51-43-4 5816
42
Pilocarpine Approved 54-71-7, 92-13-7 5910
43
Tropicamide Approved 1508-75-4 5593
44 Epinephryl borate
45 Racepinephrine
46 Autonomic Agents
47 Cholinergic Agents
48 Peripheral Nervous System Agents

Interventional clinical trials:

(show all 48)
id Name Status NCT ID Phase
1 Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves Unknown status NCT01883856 Phase 4
2 Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma Completed NCT01922154 Phase 4
3 Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma Completed NCT02647515 Phase 4
4 Intraocular Bevacizumab (Avastin) for Rubeosis Iridis Completed NCT00557232 Phase 4
5 Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4
6 TF (SENSIMED Triggerfish) in Intraocular Anti-VEGF (Vascular Endothelial Growth Factor) Injection Terminated NCT01983579 Phase 4
7 Evaluation of Efficacy and Safety of Susanna Implant in Patients With Refractory Glaucoma. Unknown status NCT01314170 Phase 3
8 Oculusgen (Ologen) Glaucoma MMC Control in Estonia Unknown status NCT00524758 Phase 3
9 Ahmed Valve Glaucoma Implant With Adjunctive Subconjunctival Bevacizumab in Refractory Glaucoma Unknown status NCT01128699 Phase 3
10 Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients Completed NCT02396316 Phase 3
11 An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. Completed NCT01908816 Phase 3
12 Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis Completed NCT02641457 Phase 3
13 Long-term Treatment Effect of Intravitreal Ant-VEGF in Branch Retinal Vein Occlusion Completed NCT02033031 Phase 3
14 Bevacizumab for Central Retinal Vein Occlusion Study Completed NCT00906685 Phase 3
15 Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery? Completed NCT00853905 Phase 2, Phase 3
16 Systemic Avastin Therapy in Age-Related Macular Degeneration Completed NCT00531024 Phase 2, Phase 3
17 Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration Recruiting NCT03034772 Phase 2, Phase 3
18 Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study Not yet recruiting NCT02914626 Phase 3
19 Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated With Proton Therapy for a Large Choroidal Melanoma Not yet recruiting NCT03172299 Phase 3
20 Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG Not yet recruiting NCT02947867 Phase 2, Phase 3
21 Avastin as an Adjunct to Diode Laser in the Treatment of Neovascular Glaucoma Completed NCT01051583 Phase 2
22 Analysis of Aqueous and Vitreous Humor Recruiting NCT02067013 Phase 2
23 Phase II Evaluating Endoresection of the Tumor Scar or Transpupillary Thermotherapy When Endoresection is Not Feasible After Proton Beam Therapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser) Recruiting NCT02874040 Phase 2
24 The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Diabetic Retinopathy Recruiting NCT03006081 Phase 2
25 Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy. Recruiting NCT02222610 Phase 2
26 Ahmed Glaucoma Valve Surgery With Mitomycin-C Not yet recruiting NCT02805257 Phase 2
27 Lucentis for New Onset Neovascular Glaucoma Withdrawn NCT00727038 Phase 1, Phase 2
28 Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion Completed NCT00406471 Phase 1
29 A Pilot Study for the Treatment of Iris Neovascularization With Macugen Completed NCT00295828 Phase 1
30 Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma Completed NCT00765921 Phase 1
31 Comparative Study, Safety and Efficacy, Ahmed Glaucoma Drainage Device, Model M4 Model S2 in Neovascular Glaucoma Unknown status NCT02260219
32 Comparison of Efficacy Between Silicone Ahmed Glaucoma Valves With and Without Intravitreal Triamcinolone Injection Unknown status NCT00491712
33 Prevalence of Glaucoma in the Israeli Arab Population Unknown status NCT01546740
34 Prospective Study Phase: Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye Unknown status NCT01348672
35 Retinal Neurodegenerative Signs in Alzheimer's Diseases Unknown status NCT01555827
36 Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma Completed NCT01370135
37 Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma Completed NCT01711879
38 Intravitreal Bevacizumab for Neovascular Glaucoma Completed NCT00384631
39 Comparison of Small-gauge Vitrectomy and Conventional Vitrectomy for Proliferative Diabetic Retinopathy Completed NCT01758757
40 Comparison of Subconjuctival Versus Topical Bevacizumab as Adjunct Therapy to Trabeculectomy Completed NCT01425112
41 The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma Recruiting NCT03154892
42 Triamcinolone for Ahmed Glaucoma Valve Recruiting NCT02653963
43 Anterior Segment Imaging With Ultrahigh-resolution OCT in Patients With Glaucoma and PEX - a Pilot Study Recruiting NCT02865473
44 Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion Active, not recruiting NCT02645747
45 Swept Source Enhanced Depth Imaging Optical Coherence Tomography Not yet recruiting NCT02443129
46 Patch Graft Material Safety and Effectiveness in Covering Glaucoma Drainage Device Tube Terminated NCT01301378
47 Radial Optic Neurotomy in Central Retinal Vein Occlusion : a Randomized Trial Terminated NCT00379223
48 Effects of Travoprost on Neovascular Glaucoma Withdrawn NCT00441181

Search NIH Clinical Center for Neovascular Glaucoma

Cochrane evidence based reviews: glaucoma, neovascular

Genetic Tests for Neovascular Glaucoma

Anatomical Context for Neovascular Glaucoma

MalaCards organs/tissues related to Neovascular Glaucoma:

39
Eye, Endothelial, Testes, Retina, Lung, Placenta

Publications for Neovascular Glaucoma

Articles related to Neovascular Glaucoma:

(show top 50) (show all 383)
id Title Authors Year
1
Reply to 'Comment on: Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab'. ( 26939556 )
2016
2
Role of Platelet Parameters on Neovascular Glaucoma: A Retrospective Case-Control Study in China. ( 27907042 )
2016
3
Study of the Effect of Injection Bevacizumab through Various Routes in Neovascular Glaucoma. ( 27536046 )
2016
4
Comment on: 'Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab'. ( 26939563 )
2016
5
Management of intraocular pressure elevation during hemodialysis of neovascular glaucoma: a case report. ( 26944556 )
2016
6
Prognostic Factor Analysis of Intraocular Pressure with Neovascular Glaucoma. ( 27579175 )
2016
7
Neovascular glaucoma: a review. ( 27895936 )
2016
8
Comparative study of the safety and efficacy of the Ahmed glaucoma valve model M4 (high density porous polyethylene) and the model S2 (polypropylene) in patients with neovascular glaucoma. ( 27068138 )
2016
9
Placenta Growth Factor in Eyes with Neovascular Glaucoma Is Decreased after Intravitreal Ranibizumab Injection. ( 26785251 )
2016
10
Evaluation of Ex-PRESS mini glaucoma shunt implantation with preoperative intracameral bevacizumab injection in refractory neovascular glaucoma. ( 26951529 )
2016
11
Intravitreal ranibizumab injection combined trabeculectomy versus Ahmed valve surgery in the treatment of neovascular glaucoma: assessment of efficacy and complications. ( 27230388 )
2016
12
Decompression retinopathy after intravitreal bevacizumab and anterior chamber paracentesis in a patient with neovascular glaucoma. ( 27958217 )
2016
13
Preoperative intravitreal injection of ranibizumab for patients with severe proliferative diabetic retinopathy contributes to a decreased risk of postoperative neovascular glaucoma. ( 27010230 )
2016
14
Paradoxical development of neovascular glaucoma following carotid angioplasty and stenting. ( 27341857 )
2016
15
Outcomes of 23-Gauge Vitrectomy Combined with Phacoemulsification, Panretinal Photocoagulation, and Trabeculectomy without Use of Anti-VEGF Agents for Neovascular Glaucoma with Vitreous Hemorrhage. ( 26885379 )
2016
16
Neovascular Glaucoma. ( 26501989 )
2016
17
Neovascular glaucoma: a retrospective review from a tertiary center in China. ( 26818828 )
2016
18
Anti-VEGF treatment is the key strategy for neovascular glaucoma management in the short term. ( 27576739 )
2016
19
Intravitreal Ranibizumab Injection as an Adjuvant in the Treatment of Neovascular Glaucoma Accompanied by Vitreous Hemorrhage after Diabetic Vitrectomy. ( 27293875 )
2016
20
Efficacy of intravitreal ranibizumab combined with Ahmed glaucoma valve implantation for the treatment of neovascular glaucoma. ( 26749079 )
2016
21
Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab. ( 26681145 )
2016
22
Bilateral neovascular glaucoma in idiopathic retinal vasculitis, aneurysms, and neuroretinitis syndrome. ( 27085273 )
2016
23
Long-Term Outcomes and Prognostic Factors of Trabeculectomy following Intraocular Bevacizumab Injection for Neovascular Glaucoma. ( 26275060 )
2015
24
Neovascular Glaucoma Post Carotid Endarterectomy: A Case Report and Review of the Literature. ( 26131030 )
2015
25
Beneficial Effects of Adjuvant Intravitreal Bevacizumab Injection on Outcomes of Ahmed Glaucoma Valve Implantation in Patients with Neovascular Glaucoma: Systematic Literature Review. ( 25714761 )
2015
26
Anti-VEGF intravitreal bevacizumab for radiation-associated neovascular glaucoma. ( 25707045 )
2015
27
Ranibizumab Plus Combined Surgery for Treatment of Neovascular Glaucoma with Vitreous Hemorrhage. ( 26228222 )
2015
28
Aflibercept for the treatment of neovascular glaucoma. ( 26016631 )
2015
29
Increase of Sialylated N-Glycansin Eyes with Neovascular Glaucoma Secondary to Proliferative Diabetic Retinopathy. ( 26177396 )
2015
30
Superficial temporal artery to middle cerebral artery anastomosis for neovascular glaucoma due to common carotid artery occlusion. ( 26167375 )
2015
31
Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: A review. ( 25980779 )
2015
32
Long-Term Results of Ahmed Glaucoma Valve in Association With Intravitreal Bevacizumab in Neovascular Glaucoma. ( 25719230 )
2015
33
Long-term Outcomes After Preoperative Intravitreal Injection of Bevacizumab Before Trabeculectomy for Neovascular Glaucoma. ( 25580888 )
2015
34
CASE-MATCHED COMPARISON OF VITRECTOMY, PERIPHERAL RETINAL ENDOLASER, AND ENDOCYCLOPHOTOCOAGULATION VERSUS STANDARD CARE IN NEOVASCULAR GLAUCOMA. ( 25621944 )
2015
35
A Prospective Study to Evaluate Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma. ( 25812531 )
2015
36
Levels of angiogenesis-related vascular endothelial growth factor family in neovascular glaucoma eyes. ( 25783445 )
2015
37
Simultaneous increase in multiple proinflammatory cytokines in the aqueous humor in neovascular glaucoma with and without intravitreal bevacizumab injection. ( 26030108 )
2015
38
Conjunctival Microangiopathy in a Patient with Neovascular Glaucoma. ( 26557840 )
2015
39
Clinical Outcomes of Ahmed Glaucoma Valve Implantation With or Without Intravitreal Bevacizumab Pretreatment for Neovascular Glaucoma: A Systematic Review and Meta-Analysis. ( 25719237 )
2015
40
The fixed combination efficacy assessment in patients with secondary neovascular glaucoma and diabetes mellitus. ( 26004082 )
2015
41
CLINICAL IMPACT IN THE MANAGEMENT OF NEOVASCULAR GLAUCOMA. ( 26978883 )
2015
42
Neovascular glaucoma: challenges we have to face. ( 24762579 )
2014
43
Neovascular glaucoma after central retinal vein occlusion in pre-existing glaucoma. ( 25282154 )
2014
44
The effect of antivascular endothelial growth factor therapy on the development of neovascular glaucoma after central retinal vein occlusion: a retrospective analysis. ( 24800060 )
2014
45
Topical bevacizumab for neovascular glaucoma: a pilot study. ( 24556733 )
2014
46
Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing ahmed glaucoma valve implantation: 2-year follow-up. ( 25488200 )
2014
47
Long-term plasmapheresis in conjunction with thalidomide and dexamethasone for the treatment of cutaneous ulcers and neovascular glaucoma in recalcitrant type I cryoglobulinemia. ( 24553496 )
2014
48
Central retinal vein occlusion and subsequent neovascular glaucoma after adalimumab treatment for psoriasis. ( 23692635 )
2014
49
Neovascular glaucoma in a child: an unusual presentation of medulloepithelioma. ( 27625938 )
2014
50
Vascular endothelial growth factor and its soluble receptors-1 and -2 in iris neovascularization and neovascular glaucoma. ( 24942011 )
2014

Variations for Neovascular Glaucoma

Expression for Neovascular Glaucoma

Search GEO for disease gene expression data for Neovascular Glaucoma.

Pathways for Neovascular Glaucoma

Pathways related to Neovascular Glaucoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 12.03 PGF TGFB2 VEGFA
2 10.97 TGFB2 VEGFA
3 10.65 TGFB2 VEGFA
4
Show member pathways
9.83 PGF VEGFA

GO Terms for Neovascular Glaucoma

Cellular components related to Neovascular Glaucoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 platelet alpha granule lumen GO:0031093 8.62 TGFB2 VEGFA

Biological processes related to Neovascular Glaucoma according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.5 PGF TGFB2 VEGFA
2 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.49 PGF VEGFA
3 positive regulation of endothelial cell proliferation GO:0001938 9.48 PGF VEGFA
4 cellular response to hormone stimulus GO:0032870 9.46 PGF UCP2
5 heart morphogenesis GO:0003007 9.43 TGFB2 VEGFA
6 activation of protein kinase activity GO:0032147 9.4 TGFB2 VEGFA
7 cell death GO:0008219 9.37 OPTN TGFB2
8 induction of positive chemotaxis GO:0050930 9.26 PGF VEGFA
9 positive regulation of mast cell chemotaxis GO:0060754 9.16 PGF VEGFA
10 positive regulation of cell division GO:0051781 9.13 PGF TGFB2 VEGFA
11 response to hypoxia GO:0001666 8.92 PGF TGFB2 UCP2 VEGFA

Molecular functions related to Neovascular Glaucoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.13 PGF TGFB2 VEGFA
2 vascular endothelial growth factor receptor binding GO:0005172 8.62 PGF VEGFA

Sources for Neovascular Glaucoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....